[{"data":1,"prerenderedAt":214},["ShallowReactive",2],{"drug-bevacizumab":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":22,"regimens":36,"contraindications":97,"warnings":98,"renal":106,"monitoring":107,"interactions":108,"review":109,"examples":112,"atc":125,"iran":127,"usApproval":147,"links":153,"populations":170},"bevacizumab",1,{"fa":7,"en":8},"بواسیزوماب","Bevacizumab","antineoplastic-immunomodulating",{"fa":11,"en":12},"آنتی‌بادی ضد VEGF","Anti-VEGF antibody",[14],{"name":15,"market":16},"Avastin","US",[18,19,7,20,21],"avastin","آواستین","stivant","استیوانت",[23],{"id":24,"form":25,"route":26,"label":27,"concentration":28,"markets":31,"refs":32},"vial-25","injection","iv","25 mg\u002FmL (100 mg\u002F4 mL, 400 mg\u002F16 mL)",{"amount":29,"unit":30,"perVolumeMl":5},25,"mg",[16],[33],{"source":34,"section":35},"fda-avastin","3",[37,71],{"id":38,"disease":39,"label":40,"population":43,"type":47,"unit":30,"dose":48,"refs":51,"durationDays":54,"notes":55},"crc5","colorectal-cancer",{"fa":41,"en":42},"سرطان کولورکتال متاستاتیک — ۵ mg\u002Fkg هر ۲ هفته (با IFL یا رژیم خط دوم)","Metastatic colorectal cancer — 5 mg\u002Fkg every 2 weeks (with IFL or second-line regimen)",{"minAge":44},{"value":45,"unit":46},18,"year","weightBased",{"perKgPerDose":49,"intervalHours":50},5,24,[52],{"source":34,"section":53},"2.2",{"min":5,"max":5},[56,64],{"text":57,"refs":60},{"fa":58,"en":59},"با FOLFOX4: ۱۰ mg\u002Fkg هر ۲ هفته؛ یا ۷٫۵ mg\u002Fkg هر ۳ هفته در خط دوم. ۲۸ روز قبل و بعد از جراحی بزرگ نه.","With FOLFOX4: 10 mg\u002Fkg every 2 weeks; or 7.5 mg\u002Fkg every 3 weeks second-line. Not within 28 days before or after major surgery.",[61,62],{"source":34,"section":53},{"source":34,"section":63},"2.1",{"text":65,"refs":68},{"fa":66,"en":67},"فقط زیر نظر پزشک متخصص انکولوژی؛ پروتکل، فاصله دوره‌ها و تنظیم با تیم درمان.","Only under an oncologist; protocol, cycle interval and adjustment rest with the treating team.",[69],{"source":34,"section":70},"2",{"id":72,"disease":73,"label":74,"population":77,"type":47,"unit":30,"dose":79,"refs":81,"durationDays":84,"notes":85},"nsclc","lung-cancer",{"fa":75,"en":76},"NSCLC غیرسنگفرشی خط اول — ۱۵ mg\u002Fkg هر ۳ هفته با کربوپلاتین و پاکلی‌تاکسل","First-line non-squamous NSCLC — 15 mg\u002Fkg every 3 weeks with carboplatin and paclitaxel",{"minAge":78},{"value":45,"unit":46},{"perKgPerDose":80,"intervalHours":50},15,[82],{"source":34,"section":83},"2.3",{"min":5,"max":5},[86],{"text":87,"refs":90},{"fa":88,"en":89},"گلیوبلاستوم عودکننده و کارسینوم کلیه: ۱۰ mg\u002Fkg هر ۲ هفته؛ سرطان سرویکس: ۱۵ mg\u002Fkg هر ۳ هفته.","Recurrent glioblastoma and renal cell carcinoma: 10 mg\u002Fkg every 2 weeks; cervical cancer: 15 mg\u002Fkg every 3 weeks.",[91,93,95],{"source":34,"section":92},"2.4",{"source":34,"section":94},"2.5",{"source":34,"section":96},"2.6",[],[99],{"text":100,"refs":103},{"fa":101,"en":102},"سوراخ‌شدگی گوارش و فیستول؛ اختلال ترمیم زخم؛ خونریزی؛ ترومبوآمبولی شریانی و وریدی؛ فشار خون؛ PRES؛ پروتئینوری؛ واکنش انفوزیون؛ نارسایی تخمدان؛ نارسایی قلب.","GI perforation and fistula; wound-healing complications; haemorrhage; arterial and venous thromboembolism; hypertension; PRES; proteinuria; infusion reactions; ovarian failure; heart failure.",[104],{"source":34,"section":105},"5",[],[],[],{"status":110,"reviewer":111,"date":111},"unverified",null,[113,120],{"regimen":38,"formulation":24,"input":114,"expect":117},{"ageYears":115,"weightKg":116},60,70,{"perDose":118,"mlPerDose":119},350,14,{"regimen":72,"formulation":24,"input":121,"expect":122},{"ageYears":115,"weightKg":116},{"perDose":123,"mlPerDose":124},1050,42,[126],"L01FG01",{"status":128,"forms":129,"refs":142},"registered",[130,134,138],{"code":131,"en":132,"fa":133},"11410","BEVACIZUMAB 100MG\u002F4ML AMP","آمپول بواسیزومب ۱۰۰ میلی‌گرم \u002F ۴ میلی‌لیتر",{"code":135,"en":136,"fa":137},"05615","BEVACIZUMAB 100MG\u002F4ML VIAL","ویال بواسیزومب ۱۰۰ میلی‌گرم \u002F ۴ میلی‌لیتر",{"code":139,"en":140,"fa":141},"05616","BEVACIZUMAB 400MG\u002F16ML VIAL","ویال بواسیزومب ۴۰۰ میلی‌گرم \u002F ۱۶ میلی‌لیتر",[143],{"source":144,"section":145,"url":146},"darooyab-generic","G-952\u002FBevacizumab","https:\u002F\u002Fwww.darooyab.ir\u002FG-952\u002FBevacizumab",{"kind":148,"refs":149,"id":152},"BLA",[150],{"source":34,"section":151},"SPL approval \u002F marketing category","BLA125085",[154,157,161,165,168],{"kind":155,"url":156,"label":152},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=125085",{"kind":158,"url":159,"label":160},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=939b5d1f-9fb2-4499-80ef-0607aa6b114e","FDA Avastin",{"kind":162,"url":163,"label":164},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa607001.html","Bevacizumab Injection",{"kind":166,"url":167,"label":126},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=L01FG01",{"kind":169,"url":146,"label":8},"darooyab",{"pregnancy":171,"lactation":180,"pediatric":188,"geriatric":197,"reproductive":206},{"level":172,"text":173,"quote":176,"refs":177},"avoid",{"fa":174,"en":175},"برچسب: می‌تواند به جنین آسیب بزند. در بارداری خطرناک است.","Label: can cause fetal harm. Dangerous in pregnancy.","Risk Summary Based on findings from animal studies and its mechanism of action [see Clinical Pharmacology (12.1) ], Avastin may cause fetal harm in pregnant women.",[178],{"source":34,"section":179},"8.1",{"level":172,"text":181,"quote":184,"refs":185},{"fa":182,"en":183},"برچسب: شیردهی توصیه نمی‌شود یا باید بین دارو و شیردهی یکی انتخاب شود.","Label: breastfeeding not recommended, or choose between the drug and breastfeeding.","Because of the potential for serious adverse reactions in breastfed infants, advise women not to breastfeed during treatment with Avastin and for 6 months after the last dose.",[186],{"source":34,"section":187},"8.2",{"level":189,"text":190,"quote":193,"refs":194},"not-established",{"fa":191,"en":192},"برچسب: ایمنی و اثربخشی در کودکان ثابت نشده است.","Label: safety and effectiveness in children have not been established.","The safety and effectiveness of Avastin in pediatric patients have not been established.",[195],{"source":34,"section":196},"8.4",{"level":198,"text":199,"quote":202,"refs":203},"caution",{"fa":200,"en":201},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","…  ATE was greater in patients ≥ 65 years (8% vs. 3%) as compared to patients \u003C 65 years (2% vs. 1%) [see Warnings and Precautions (5.4) ].",[204],{"source":34,"section":205},"8.5",{"level":198,"text":207,"quote":210,"refs":211},{"fa":208,"en":209},"برچسب نکته‌ای درباره بارداری، پیشگیری یا باروری زنان و مردان دارد.","Label has advice on pregnancy testing, contraception or fertility for females and males.","Contraception Females Avastin may cause fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1) ] .",[212],{"source":34,"section":213},"8.3",1792444381490]